The development of tyrosine kinase inhibior (TKI) has greatly altered the standard of care for advanced NSCLC with driver gene mutations, for example, epidermal growth factor receptor (EGFR) sensitive mutation [2] and anaplastic lymphoma kinase (ALK) mutation [3]. Here, ALK is linked to non-small cell lung carcinoma.